Claims for Patent: 4,001,409

Summary for Patent: 4,001,409

Title:	Injectable formulations of 7-[D-.alpha.-amino-.alpha.-(p-hydroxyphenyl)acetamido]-3-(1,2,3-triazol- 5-ylthiomethyl)-3-cephem-4-carboxylic acid
Abstract:	Antibacterial compositions comprising 7-[D-.alpha.-amino-.alpha.-(p-hydroxyphenyl)acetamido]-3-(1,2,3-triazol-5- ylthiomethyl)-3-cephem-4-carboxylic acid in the form of a hydrate or a hydrochloride salt and a sodium, potassium or calcium salt of levulinic acid have been found to be stable, useful, water-soluble forms of the cephalosporin antibiotic especially advantageous for parenteral administration.
Inventor(s):	Granatek; Alphonse Peter (Baldwinsville, NY), Kaplan; Murray Arthur (Syracuse, NY)
Assignee:	Bristol-Myers Company (New York, NY)
Application Number:	05/580,268
Patent Claims:	1. A stable, solid, water-soluble antibiotic composition for reconstitution upon addition of sterile water as a stable injectable solution of 7-[D-.alpha.-amino-.alpha.-(p-hydroxyphenyl)acetamido]-3-(1,2,3-triazol-5- ylthiomethyl)-3-cephem-4-carboxylic acid, said composition comprising a mixture of one part by weight of 7-[D-.alpha.-amino-.alpha.-(p-hydroxyphenyl)acetamido]-3-(1,2,3-triazol-5- ylthiomethyl)-3-cephem-4-carboxylic acid hydrate and about 0.25 to about 2.0 parts by weight of sodium, potassium or calcium levulinate. 2. The composition of claim 1 wherein the 7-[D-.alpha.-amino-.alpha.-(p-hydroxyphenyl)acetamido]-3-(1,2,3-triazol-5- ylthiomethyl)-3-cephem-4-carboxylic acid hydrate is the amorphous monohydrate. 3. The composition of claim 2 wherein the levulinic acid salt is sodium levulinate. 4. The composition of claim 3 suitable upon reconstitution with sterile water as a stable pH 4.5 to 7.8 injectable solution of 7-[D-.alpha.-amino-.alpha.(p-hydroxyphenyl)acetamido]-3-(1,2,3-triazol-5-y lthiomethyl)-3-cephem-4-carboxylic acid, said composition comprising a mixture of one part by weight of amorphous cephalosporanic acid monohydrate and about 0.75 to 1.0 parts by weight of sodium levulinate. 5. The stable injectable preparation of 7-[D-.alpha.-amino-.alpha.-(p-hydroxyphenyl)acetamido]-3-(1,2,3-triazol-5- ylthiomethyl)-3-cephem-4-carboxylic acid, said preparation comprising in aqueous solution one part by weight of 7-[D-.alpha.-amino-.alpha.-(p-hydroxyphenyl)acetamido]-3-(1,2,3-triazol-5- ylthiomethyl-3-cephem-4-carboxylic acid hydrate or hydrochloride and about 0.25 to about 2.0 parts by weight of sodium, potassium or calcium levulinate and having a pH in the range of 3.5 to 8.0. 6. The preparation of claim 5 wherein the cephalosporanic acid compound is the amorphous monohydrate or amorphous mono-hydrochloride. 7. The preparation of claim 6 wherein the levulinic acid salt is sodium levulinate. 8. The preparation of claim 7 wherein the cephalosporanic acid compound and levulinate are employed in a ratio of about 1:0.75-1.0, respectively, to give a pH 4.5 to 7.8 solution. 9. The preparation of claim 8 wherein the concentration of 7-[D-.alpha.-amino-.alpha.-(p-hydroxyphenyl)acetamido]-3-(1,2,3-triazol-5- ylthiomethyl)-3-cephem-4-carboxylic acid provided in solution is from about 10 to 350 mg./ml. of solution. 10. The preparation of claim 9 wherein the cephalosporanic acid compound is 200 mesh amorphous monohydrate. 11. A process for the preparation of a stable, solid, water-soluble composition suitable upon reconstitution with sterile water as a stable injectable solution of 7-[D-.alpha.amino-.alpha.-(p-hydroxyphenyl)acetamido]-3-(1,2,3-triazol-5-y lthiomethyl)-3-cephem-4-carboxylic acid; which process comprises 1. forming an aqueous solution of one part by weight of 7-[D-.alpha.-amino-.alpha.-(p-hydroxyphenyl)acetamido]-3-(1,2,3-triazol-5- ylthiomethyl)-3-cephem-4-carboxylic acid hydrate or hydrochloride and about 0.25 to about 2.0 parts by weight of sodium, potassium or calcium levulinate; and 2. lyophilizing the so-produced aqueous solution to produce the desired solid composition. 12. The process of claim 11 wherein the cephalosporanic acid compound is the amorphous monohydrate or amorphous mono-hydrochloride. 13. The process of claim 12 wherein the levulinic acid salt is sodium levulinate. 14. The process of claim 13 wherein the cephalosporanic acid compound and sodium levulinate are employed in a proportion of about 1:0.75-1.0, respectively. 15. The process of claim 14 wherein the aqueous solution of Step (1) comprises about one gram of cephalosporanic acid compound and about 0.8 to 0.85 grams of sodium levulinate per 2.5 to 3.0 ml. of water. 16. A process for the preparation of a stable, solid, water-soluble composition suitable upon reconstitution with sterile water as a stable injectable solution of 7-[D-.alpha.-amino-.alpha.-(p-hydroxyphenyl)acetamido]-3-(1,2,3-triazol-5- ylthiomethyl)-3-cephem-4-carboxylic acid; which process comprises 1. forming an aqueous solution of one part by weight of 7-[D-.alpha.-amino-.alpha.-(p-hydroxyphenyl)acetamido]-3-(1,2,3-triazol-5- ylthiomethyl)-3-cephem-4-carboxylic acid hydrate or hydrochloride and about 0.25 to about 2.0 parts by weight of sodium, potassium or calcium levulinate; and 2. adding the so-produced aqueous solution to a sufficient quantity of ethanol, n-propanol or isopropanol to effect precipitation of the desired solid composition. 17. The process of claim 16 wherein the cephalosporanic acid compound is the amorphous monohydrate or amorphous mono-hydrochloride. 18. The process of claim 17 wherein the levulinic acid salt is sodium levulinate. 19. The process of claim 18 wherein the cephalosporanic acid compound and sodium levulinate are employed in a proportion of about 1:0.75-1.0, respectively. 20. The process of claim 19 wherein the aqueous solution of Step (1) comprises about one gram of cephalosporanic acid compound and about 0.8 to 0.85 grams of sodium levulinate per 2.5 to 3.0 ml. of water. 21. The process of claim 20 wherein the aqueous solution of Step (1) is added with rapid stirring to about 15 to 20 volumes of the ethanol, n-propanol or isopropanol.

Details for Patent 4,001,409

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-23